Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00615511 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Pregnenolone in Patients With Schizophrenia
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00615511 is a Phase 2 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 100 participants.
The verdict
NCT00615511, a Phase 2 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
Four-month trial of pregnenolone or placebo, as an additional medication, to treat negative symptoms and cognitive decline in schizophrenia. After four months the scores on the negative symptom scale should be lower and the scores on the cognitive tests should be higher than they were at study entry, compared with people who do not take any additional medication.
Interventions
- DIETARY_SUPPLEMENT pregnenolone
- DIETARY_SUPPLEMENT placebo pregnenolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2007-06 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00615511
The ClinicalTrials.gov registry entry for NCT00615511 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pregnenolone is the first listed.
NCT00615511 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00615511 about?
NCT00615511 is a clinical study titled "Efficacy of Pregnenolone in Patients With Schizophrenia". Four-month trial of pregnenolone or placebo, as an additional medication, to treat negative symptoms and cognitive decline in schizophrenia. After four months the scores on the negative symptom scale should be lower and the scores on the cognitive tests should be higher than they were at study entry...
What is the current status of trial NCT00615511?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2007-06. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00615511?
The interventions under investigation include: pregnenolone (DIETARY_SUPPLEMENT), placebo pregnenolone (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00615511?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.